John Shearer

KO client Kailera Therapeutics, a clinical-stage biotechnology company focused on elevating the next era of obesity care, recently announced positive topline data from two Phase 3 clinical trials for people living with obesity or type 2 diabetes. KO partner Brad Schoenfeld and attorney John Shearer represented Kailera in getting the…

KO client Elpida Therapeutics, a nonprofit biotechnology company dedicated to developing treatments for ultra-rare pediatric neurological diseases, recently announced that it has entered into an assignment and license agreement with Ionis Pharmaceuticals for ION283, an investigational antisense oligonucleotide (ASO) therapy for Lafora disease. The agreement is expected to advance the…

KO client Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy recently announced a license agreement to develop a gene therapy using Apertura’s TfR1 CapX technology. “Although FRRS1L is a horrible and devastating disease robbing children of…